TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32977309

Group type: EXPERIMENTAL
Intervention: 124I-8H9 monoclonal antibody (124I-omburtamab) administered by CED
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Second infusion of 124I-8H9 monoclonal antibody (124I-omburtamab)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: First and second infusions of 124I-8H9 monoclonal antibody (124I-omburtamab)
Number of subjects: 7
Study: 32977351

Group type: EXPERIMENTAL
Intervention: Niprisan
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo or conventional treatment (including blood transfusion and hydroxyurea)
Number of subjects: 212
Study: 32977785

Group type: EXPERIMENTAL
Intervention: Free musical training programme
Number of subjects: 171
Study: 32977798

Group type: EXPERIMENTAL
Intervention: Switch intervention
Number of subjects: 3
Study: 32977802

Group type: EXPERIMENTAL
Intervention: Long-term glycemic variability (GV)
Number of subjects: 396
Study: 32977906

Group type: EXPERIMENTAL
Intervention: Supine position
Number of subjects: 1600

Group type: COMPARATOR
Intervention: Standing position
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Right side of the body (standing)
Number of subjects: 1600

Group type: EXPERIMENTAL
Intervention: Right side of the body (supine)
Number of subjects: 1600
Study: 32978101

Group type: EXPERIMENTAL
Intervention: Tyrosine and serine/threonine kinase inhibitors (TKIs)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Use of at least three concomitant medications
Number of subjects: 0
Study: 32978191

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32978195

Group type: EXPERIMENTAL
Intervention: Clinical prediction model derived using logistic regression
Number of subjects: 370

Group type: EXPERIMENTAL
Intervention: External validation using the Therapeutic Hypothermia After Paediatric Cardiac Arrest trial dataset
Number of subjects: 370
Study: 32978206

Group type: EXPERIMENTAL
Intervention: Wireless sensor (myAngel VitalSigns, Devinnova, Montpellier, France)
Number of subjects: 115

Group type: COMPARATOR
Intervention: Standard bedside monitor (Carescape Monitor B850, GE Healthcare, Chicago, Illinois)
Number of subjects: 115
Study: 32978212

Group type: EXPERIMENTAL
Intervention: BCG vaccine (at birth)
Number of subjects: 6012

Group type: EXPERIMENTAL
Intervention: BCG reactors (having a 2-month reaction)
Number of subjects: 6012

Group type: EXPERIMENTAL
Intervention: Reaction size tertiles
Number of subjects: 6012

Group type: EXPERIMENTAL
Intervention: BCG vaccine (4-week evaluation)
Number of subjects: 6012
Study: 32978218

Group type: EXPERIMENTAL
Intervention: Pharmacist-led educational programme consisting of individual semi-structured interviews and follow-up telephone interviews over 1 year.
Number of subjects: 182

Group type: COMPARATOR
Intervention: Standard care (control group).
Number of subjects: 182
Study: 32978233

Group type: EXPERIMENTAL
Intervention: High Glycemic Burden
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32978352

Group type: EXPERIMENTAL
Intervention: 0.5% bupivacaine solution
Number of subjects: 114

Group type: COMPARATOR
Intervention: Normal saline solution
Number of subjects: 114
Study: 32979032

Group type: EXPERIMENTAL
Intervention: Normal pregnancy
Number of subjects: 115

Group type: EXPERIMENTAL
Intervention: Preeclampsia
Number of subjects: 115

Group type: COMPARATOR
Intervention: Intrauterine growth restriction
Number of subjects: 115

Group type: COMPARATOR
Intervention: Healthy non-pregnant women
Number of subjects: 115
Study: 32979106

Group type: EXPERIMENTAL
Intervention: Docetaxel (D) 75 mg/m²
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pegylated liposomal doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of docetaxel and pegylated liposomal doxorubicin
Number of subjects: 0
Study: 32979511

Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Number of subjects: 143
Study: 32979535

Group type: EXPERIMENTAL
Intervention: Low intraperitoneal pressure (IPP) at 6 mm Hg and warmed, humidified carbon dioxide gas
Number of subjects: 30
Study: 32979560

Group type: EXPERIMENTAL
Intervention: Adjunctive brexpiprazole 2-3 mg/day for 8 weeks
Number of subjects: 9
Study: 32979640

Group type: EXPERIMENTAL
Intervention: Patients walking over 350 m
Number of subjects: 516

Group type: COMPARATOR
Intervention: Other groups (walking less than 350 m)
Number of subjects: 516
Study: 32979785

Group type: EXPERIMENTAL
Intervention: Patients with clinically relevant anxiety (A+)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Patients without clinically relevant anxiety (A-)
Number of subjects: 118
Study: 32979984

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with intravenous paclitaxel (200 mg/m2) and nivolumab
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Neoadjuvant treatment with intravenous paclitaxel and nivolumab
Number of subjects: 46
Study: 32980206

Group type: EXPERIMENTAL
Intervention: Sleep spindle activity in patients with COS
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Non-rapid eye movement (NREM) sleep EEG power and coherence in the sigma band (11-16 Hz)
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Deficit in power and coherence of spindles
Number of subjects: 17
Study: 32980364

Group type: EXPERIMENTAL
Intervention: Sacubitril/valsartan
Number of subjects: 270

Group type: COMPARATOR
Intervention: Control (recent ACE inhibitor/ARB initiation/dose change)
Number of subjects: 270
Study: 32980370

Group type: EXPERIMENTAL
Intervention: 14 nights of pulse oximetry (PO) at home
Number of subjects: 103

Group type: EXPERIMENTAL
Intervention: Multiple study nights using ambulatory oxygen saturation monitoring
Number of subjects: 103
Study: 32980834

Group type: EXPERIMENTAL
Intervention: ω-3 fatty acids and low-dose aspirin as adjuncts to periodontal debridement
Number of subjects: 1
Study: 32981423

Group type: EXPERIMENTAL
Intervention: Women without diabetes mellitus
Number of subjects: 14793

Group type: EXPERIMENTAL
Intervention: Women with diabetes mellitus
Number of subjects: 14793

Group type: COMPARATOR
Intervention: Men without diabetes mellitus
Number of subjects: 14793

Group type: COMPARATOR
Intervention: Men with diabetes mellitus
Number of subjects: 14793
Study: 32982148

Group type: EXPERIMENTAL
Intervention: GoCheck Kids (GCK) photoscreener
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: 2WIN photoscreener
Number of subjects: 131

Group type: EXPERIMENTAL
Intervention: Retinomax autorefractor
Number of subjects: 131
Study: 32982210

Group type: EXPERIMENTAL
Intervention: Enjoying Breathing Program intervention including online and face-to-face courses for health care providers, standard therapy, self-management education, rehabilitation exercises, and follow-up every 3 months.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enjoying Breathing Program intervention
Number of subjects: 0
Study: 32982387

Group type: EXPERIMENTAL
Intervention: Preoperative dinalbuphine sebacate (DS)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Post-operative morphine
Number of subjects: 44
Study: 32982388

Group type: EXPERIMENTAL
Intervention: Patient-reported physical function
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Performance-based physical function
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Objective physical function
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pain and non-adaptive coping
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Adaptive coping
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Social-emotional dysfunction
Number of subjects: 79
Study: 32982393

Group type: EXPERIMENTAL
Intervention: a-tDCS/HS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: a-tDCS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: HS
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: s-tDCS/HS
Number of subjects: 48
Study: 32982924

Group type: EXPERIMENTAL
Intervention: Canal repositioning maneuver
Number of subjects: 24
Study: 32982933

Group type: EXPERIMENTAL
Intervention: Purified Anthocyanins, dosage and duration not available
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group, details not available
Number of subjects: 0
Study: 32982944

Group type: EXPERIMENTAL
Intervention: High Dose of Atorvastatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 32982950

Group type: EXPERIMENTAL
Intervention: Combined therapy of Virtual Reality and Transcranial Direct Current Stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32982963

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 293
Study: 32983160

Group type: EXPERIMENTAL
Intervention: Thirty-eight-negative kinase 1 (TNK1) intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32983243

Group type: EXPERIMENTAL
Intervention: 6-week weight loss camp including aerobic exercise and dietary control
Number of subjects: 79
Study: 32983551

Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Number of subjects: 114

Group type: COMPARATOR
Intervention: LowGI/nutrigenetic diet
Number of subjects: 114
Study: 32983557

Group type: EXPERIMENTAL
Intervention: Preoperative tattooing of suspicious axillary lymph node with India ink at the time of core needle biopsy during SLNB.
Number of subjects: 40
Study: 32983839

Group type: EXPERIMENTAL
Intervention: Usual care plus patient-tailored adherence interventions
Number of subjects: 438

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 438
Study: 32983965

Group type: EXPERIMENTAL
Intervention: GZ17-6.02 (602) + Doxorubicin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GZ17-6.02 (602) alone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Doxorubicin + GZ17-6.02
Number of subjects: 0
Study: 32983991

Group type: EXPERIMENTAL
Intervention: S-1-based chemoradiotherapy followed by consolidation chemotherapy with S-1
Number of subjects: 0
Study: 32984371

Group type: EXPERIMENTAL
Intervention: Non-invasive drug monitoring of β-Lactam antibiotics using sweat analysis
Number of subjects: 0
Study: 32985119

Group type: EXPERIMENTAL
Intervention: Individualized nonshivering cold exposure
Number of subjects: 44
Study: 32985406

Group type: EXPERIMENTAL
Intervention: Pittsburgh Sleep Quality Index (PSQI)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: PSQI components (poorer sleep quality and greater sleep disturbance)
Number of subjects: 203

Group type: EXPERIMENTAL
Intervention: Increased sleep latency and daytime sleepiness
Number of subjects: 203
Study: 32985724

Group type: EXPERIMENTAL
Intervention: Surgical AF ablation
Number of subjects: 2391
Study: 32985924

Group type: EXPERIMENTAL
Intervention: Hemigland cryoablation
Number of subjects: 61
Study: 32987448

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 3034

Group type: COMPARATOR
Intervention: Antibiotics
Number of subjects: 3034

Group type: COMPARATOR
Intervention: Fusidic acid ointment
Number of subjects: 3034

Group type: COMPARATOR
Intervention: Mupirocin ointment
Number of subjects: 3034

Group type: COMPARATOR
Intervention: Specialist breastfeeding education
Number of subjects: 3034

Group type: COMPARATOR
Intervention: Anti-secretory factor-inducing cereal
Number of subjects: 3034

Group type: EXPERIMENTAL
Intervention: Acupoint massage
Number of subjects: 3034

Group type: EXPERIMENTAL
Intervention: Breast massage and low frequency pulse treatment
Number of subjects: 3034
Study: 32987824

Group type: EXPERIMENTAL
Intervention: Oral glucose tolerance tests (OGTT) with doses of 25 g, 75 g, and 125 g
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isoglycaemic intravenous (i.v.) glucose infusions (IIGI)
Number of subjects: 16
Study: 32988240

Group type: EXPERIMENTAL
Intervention: ECEQ-T (Turkish version of the European Child Environment Questionnaire)
Number of subjects: 306

Group type: EXPERIMENTAL
Intervention: Test-retest reliability of ECEQ-T
Number of subjects: 306
Study: 32988817

Group type: EXPERIMENTAL
Intervention: Extended-spectrum-beta-lactamase (ESBL)-producing members
Number of subjects: 0
Study: 32988829

Group type: EXPERIMENTAL
Intervention: Intravenous acyclovir (10 mg/kg of body weight/6 h)
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Oral acyclovir
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Both intravenous and oral acyclovir
Number of subjects: 79

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 79
Study: 32988939

Group type: EXPERIMENTAL
Intervention: Behaviour change interventions delivered by Norwegian Healthy Life Centres (HLCs)
Number of subjects: 713
Study: 32988948

Group type: EXPERIMENTAL
Intervention: Oral steroids, intratympanic steroid injections, or a combination of both (exact dosages and durations not specified)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivariable prognostic model using prespecified candidate predictors
Number of subjects: 0
Study: 32988996

Group type: EXPERIMENTAL
Intervention: Pertuzumab and trastuzumab-emtansine (T-DM1)
Number of subjects: 31
Study: 32989031

Group type: EXPERIMENTAL
Intervention: Endovascular treatment
Number of subjects: 65
Study: 32989226

Group type: EXPERIMENTAL
Intervention: ODM-207 (2 mg/kg)
Number of subjects: 35
Study: 32989425

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 7000
Study: 32989495

Group type: EXPERIMENTAL
Intervention: Three cycles of abbreviated R-CHOP
Number of subjects: 0
Study: 32989552

Group type: EXPERIMENTAL
Intervention: JTX-4014 (500 mg every 3 weeks or 1000 mg every 6 weeks)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: JTX-4014
Number of subjects: 18
Study: 32989575

Group type: EXPERIMENTAL
Intervention: Severely food insecure women
Number of subjects: 371

Group type: COMPARATOR
Intervention: Food-secure women
Number of subjects: 371
Study: 32989612

Group type: EXPERIMENTAL
Intervention: TIMI 0-1 group (n=219)
Number of subjects: 329

Group type: COMPARATOR
Intervention: TIMI 2-3 group (n=110)
Number of subjects: 329
Study: 32989616

Group type: EXPERIMENTAL
Intervention: Episodic Future Thinking (EFT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control episodic recent thinking
Number of subjects: 0

Group type: COMPARATOR
Intervention: Economic scarcity narrative
Number of subjects: 0
Study: 32989776

Group type: EXPERIMENTAL
Intervention: First-line tyrosine kinase inhibitors (TKIs)
Number of subjects: 431

Group type: COMPARATOR
Intervention: Non-switchers
Number of subjects: 431

Group type: EXPERIMENTAL
Intervention: Switchers
Number of subjects: 431
Study: 32989856

Group type: EXPERIMENTAL
Intervention: Convalescent plasma treatment
Number of subjects: 4
Study: 32990181

Group type: EXPERIMENTAL
Intervention: HPV16
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: Carcinogenic HPVs in nonavalent vaccine (HPV16,18,31,33,45,52,58)
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: HPV types not vaccinated against (HPV35,39,51,56,59,66,68)
Number of subjects: 8351

Group type: EXPERIMENTAL
Intervention: Other 27 non-carcinogenic genotypes
Number of subjects: 8351
Study: 32990248

Group type: EXPERIMENTAL
Intervention: Cognitive behavioral intervention
Number of subjects: 266

Group type: EXPERIMENTAL
Intervention: Mindfulness-based intervention
Number of subjects: 266

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 266
Study: 32990250

Group type: EXPERIMENTAL
Intervention: Web-enabled clinical decision support system for physical activity and diet
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no web-enabled clinical decision support system)
Number of subjects: 0
Study: 32990324

Group type: COMPARATOR
Intervention: Mepolizumab (300 mg; three separate injections every four weeks for 52 weeks)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Mepolizumab (300 mg)
Number of subjects: 440

Group type: COMPARATOR
Intervention: Etanercept (25 mg twice a week) or Belimumab (10 mg/kg on days 0, 14, 28 and every 28 days thereafter until 12 months after the last participant was randomised) with standard therapy
Number of subjects: 440

Group type: COMPARATOR
Intervention: Etanercept (25 mg twice a week)
Number of subjects: 440
Study: 32990629

Group type: EXPERIMENTAL
Intervention: Video directly observed therapy (VDOT) with smartphone app, weekly internet subscription, translated text message reminders, and incentives for adherence
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual-care directly observed therapy (DOT)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: VDOT
Number of subjects: 144

Group type: COMPARATOR
Intervention: Usual-care DOT
Number of subjects: 144
Study: 32990836

Group type: EXPERIMENTAL
Intervention: ECCO
Number of subjects: 12
Study: 32990938

Group type: EXPERIMENTAL
Intervention: Extended-release dinalbuphine sebacate (ERDS)
Number of subjects: 110

Group type: COMPARATOR
Intervention: Intravenous patient-controlled analgesia (PCA) with fentanyl
Number of subjects: 110
Study: 32990945

Group type: COMPARATOR
Intervention: Pine bark extract supplements
Number of subjects: 1641
Study: 32991114

Group type: EXPERIMENTAL
Intervention: Elderly group (≥ 65 years)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Overall recurrence of VTE
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Bleeding events
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Age and recurrence association
Number of subjects: 446
Study: 32991242

Group type: EXPERIMENTAL
Intervention: Digital Breast Tomosynthesis (DBT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional breast cancer screening methods
Number of subjects: 0
Study: 32991329

Group type: EXPERIMENTAL
Intervention: IgG against SARS-CoV-2 spike RBD
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Antibodies to multiple SARS-CoV-2 antigens
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: IgG to the RBD
Number of subjects: 509

Group type: EXPERIMENTAL
Intervention: Antibodies to HCoV-OC43 and HCoV-HKU1 spike S2
Number of subjects: 509

Group type: COMPARATOR
Intervention: Coinfection with influenza
Number of subjects: 509
Study: 32991411

Group type: EXPERIMENTAL
Intervention: Tacrolimus-based immunosuppression
Number of subjects: 100
Study: 32992048

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting-enzyme inhibitors (ACEI)
Number of subjects: 4069

Group type: EXPERIMENTAL
Intervention: Angiotensin-receptor blockers (ARB)
Number of subjects: 4069

Group type: EXPERIMENTAL
Intervention: ACEI or ARB combined
Number of subjects: 4069

Group type: EXPERIMENTAL
Intervention: Meta-analysis of 19 studies
Number of subjects: 4069
Study: 32992341

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy (3 cycles) followed by AVD chemotherapy (4 to 6 cycles)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: AVD chemotherapy (after pembrolizumab)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Pembrolizumab monotherapy followed by AVD
Number of subjects: 30
Study: 32993275

Group type: EXPERIMENTAL
Intervention: BPH screening tool (score ≥3) and serum PSA ≥2 ng/mL
Number of subjects: 561

Group type: COMPARATOR
Intervention: IPSS ≥8 and serum PSA ≥2 ng/mL
Number of subjects: 561
Study: 32993521

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels measured prior to catheter ablation
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: C-reactive protein (CRP) levels analyzed as continuous variable
Number of subjects: 711

Group type: EXPERIMENTAL
Intervention: CRP cut-off of 3 mg/l
Number of subjects: 711
Study: 32993559

Group type: EXPERIMENTAL
Intervention: UCP-LF CAA urine test
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PZQ treatment immediately after diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: PZQ treatment after delivery
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Longitudinal study
Number of subjects: 0
Study: 32993716

Group type: EXPERIMENTAL
Intervention: Routine preoperative carotid and lower limb ultrasound screening
Number of subjects: 360
Study: 32993772

Group type: EXPERIMENTAL
Intervention: Total alpha-synuclein levels in CSF in AD patients
Number of subjects: 166

Group type: COMPARATOR
Intervention: Total alpha-synuclein levels in CSF in DLB patients
Number of subjects: 166

Group type: COMPARATOR
Intervention: Combination of Alzheimer's biomarkers (t-Tau, P-Tau, Aβ42, Aβ40)
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Total alpha-synuclein levels in CSF
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Adding alpha-synuclein total to Alzheimer's biomarkers
Number of subjects: 166
Study: 32993784

Group type: EXPERIMENTAL
Intervention: Tocilizumab treatment
Number of subjects: 107
Study: 32993794

Group type: EXPERIMENTAL
Intervention: BEZ235 (300-400 mg BID)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BEZ235 (300 mg BID)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: BEZ235
Number of subjects: 24
Study: 32993811

Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (PEEP) (12-15 cmH2O)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: High positive end-expiratory pressure (PEEP)
Number of subjects: 30
Study: 32994225

Group type: EXPERIMENTAL
Intervention: FBG variability (measured using SD, CV, VIM, and average real variability)
Number of subjects: 7699
Study: 32994243

Group type: EXPERIMENTAL
Intervention: Exclusive use of liquefied petroleum gas (LPG)
Number of subjects: 0
Study: 32994273

Group type: EXPERIMENTAL
Intervention: STAT1 deletion in adipocytes
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 32994296

Group type: EXPERIMENTAL
Intervention: Marlboro Gold (n=49)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Marlboro Red (n=191)
Number of subjects: 240
Study: 32994312

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion (BPD) or Roux-en-Y gastric bypass (RYGB)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Bypassing the jejunum
Number of subjects: 24
Study: 32994362

Group type: EXPERIMENTAL
Intervention: Immune-mediated inflammatory diseases (IMID)
Number of subjects: 53378

Group type: EXPERIMENTAL
Intervention: Crohn's disease (CD)
Number of subjects: 53378

Group type: EXPERIMENTAL
Intervention: Ulcerative colitis
Number of subjects: 53378

Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis (RA)
Number of subjects: 53378

Group type: EXPERIMENTAL
Intervention: Psoriatic arthritis (PsA)
Number of subjects: 53378
Study: 32994371

Group type: EXPERIMENTAL
Intervention: Shuxuetong injection
Number of subjects: 2416

Group type: COMPARATOR
Intervention: Placebo injection
Number of subjects: 2416
Study: 32994442

Group type: EXPERIMENTAL
Intervention: Colonoscopy use in non-genetic testing (NGT) individuals
Number of subjects: 176

Group type: COMPARATOR
Intervention: Colonoscopy use in carriers of Lynch syndrome
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Perceived risk to develop colon cancer
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Physician recommendations for colonoscopy
Number of subjects: 176
Study: 32995696

Group type: EXPERIMENTAL
Intervention: Asfotase alfa for 12 months
Number of subjects: 14